CSC DVC Press Releases

Global Site | Contact Us | CSC Portal

Home

DVC LLC

DVC Press Releases

DynPort Vaccine Company LLC (DVC) is a wholly owned subsidiary of CSC. Press releases issued by CSC about DVC are included on this page. Visit the CSC newsroom to view all CSC press releases.

CSC’S DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit CSC announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
CSC’S DynPort Vaccine Company to Continue Plague Vaccine Development CSC announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has been notified by the Department of Defense (DoD) that all future funding for advanced development of plague vaccine will be allocated to the existing DVC contract with the Joint Project Manager Chemical, Biological and Medical Systems’ Joint Vaccine Acquisition Program (JVAP) Joint Product Management Office.
U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSC’S DVC and Baxter CSC today announced that DynPort Vaccine Company LLC (DVC), a CSC company, in conjunction with Baxter International Inc. (NYSE: BAX), has received a $201.2 million contract modification from the U.S. Department of Health and Human Services (HHS) for the development of Baxter’s cell-cultured seasonal and pandemic influenza candidate vaccines.
CSC's DVC Achieves Significant Milestones in Department of Defense Contract CSC today announced that DynPort Vaccine Company LLC (DVC), a CSC company, has made significant progress on several biodefense vaccine development programs it manages for the U.S. Department of Defense Joint Vaccine Acquisition Program (JVAP).
CSC's DVC and Baxter Begin Phase 1 Clinical Trial for Chemical Defense Product CSC today announced that DynPort Vaccine Company LLC (DVC), a CSC company, in conjunction with Baxter Healthcare Corporation, has initiated a Phase 1 clinical trial for plasma-derived butyrylcholinesterase, or “BioScavenger,” which is being developed to prevent and possibly treat effects of exposure to certain chemical nerve agents.
CSC’S DVC Begins Phase 2 Clinical Trial For Plague Vaccine Candidate CSC today announced that DynPort Vaccine Company LLC (DVC), a CSC company, has entered into a phase 2 clinical trial for its recombinant plague vaccine candidate, rF1V.
CSC's DVC Wins $242.5 Million DHHS Contract to Develop Influenza Vaccines CSC today announced that DVC LLC, a CSC company, has been awarded a contract from the U.S. Department of Health and Human Services (DHHS) Office of Public Health Emergency Preparedness to develop seasonal and pandemic influenza vaccines in support of the establishment of a diversified influenza manufacturing industry.
Dr. Robert V. House Appointed President of CSC’s DVC LLC Vaccine Business CSC today announced that Robert V. House, Ph.D., has been appointed President of DVC LLC, a CSC company. Since 2005, House has served as Chief Scientific Officer of DVC, and continues to serve in that capacity.
CSC's DVC Reaches Milestone in Plague Vaccine Clinical Trial CSC today announced that DVC LLC, a CSC company, has successfully vaccinated all volunteers in a phase 1 clinical trial for its recombinant plague vaccine candidate rF1V.
CSC Wins $35.1 Million NIAID Contract for Development of Tularemia Vaccine CSC today announced that DVC LLC, a CSC company, has been awarded a five-year, $35.1 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to develop candidates for a safe and effective tularemia vaccine.
FDA Grants Fast Track Designation to DVC Biodefense Vaccine Development Programs CSC today announced that DVC LLC, a CSC company, has received Fast Track designation status from the U.S. Food and Drug Administration (FDA) for three biodefense vaccine development programs it is working on for the Department of Defense Joint Vaccine Acquisition Program (JVAP) Product Management Office.
CSC’S DVC Enters Clinical Trial for Venezuelan Equine Encephalitis Vaccine Candidate CSC today announced that DVC LLC, a CSC company, has entered into a phase 1 clinical trial for its Venezuelan equine encephalitis (VEE) vaccine candidate V3526.
CSC Wins $19.6 Million Contract for Advanced Development of Chemical Nerve Agent Treatment CSC today announced that DVC LLC, a CSC company, has been awarded a two-year, $19.6 million contract from the Department of Defense Medical Identification and Treatment Systems (MITS) Joint Product Management Office to develop plasma-derived human butyrylcholinesterase.
DVC Announces FDA Approval of Vaccinia Immune Globulin to Treat Adverse Reactions to Smallpox Vaccination CSC today announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination.
CSC's DVC Enters Clinical Trial for Plague Vaccine Candidate CSC today announced that DVC LLC, a CSC company, has entered into a phase 1 clinical trial for its recombinant plague vaccine candidate.
CSC Wins $19.7 Million Award for Advanced Development of Biodefense Vaccines CSC today announced that DVC LLC, a CSC company, has been awarded approximately $19.7 million in grants and contract modifications from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health.
CSC's DVC Enters Clinical Trial for Botulinum Neurotoxin Vaccine Candidate CSC today announced that DVC, a CSC company, has entered into a phase 1 clinical trial for its recombinant botulinum neurotoxin vaccine candidate.
CSC Acquires Full Interest in Biopharmaceutical Company DVC CSC today announced that it has acquired Porton International Inc.’s interest in DynPort Vaccine Company LLC (DVC), a biopharmaceutical company focused on the development of biodefense biologics products.
DVC Announces FDA Acceptance for Filing of Vaccinia Immune Globulin BLA CSC today announced that the U.S. Food and Drug Administration has accepted DynPort Vaccine Company’s filing of a Biologics License Application for Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin under evaluation for the treatment of adverse reactions to smallpox vaccination.
CSC Joint Venture DynPort Complete Phase 1 Smallpox Vaccine Trial CSC announced today that DynPort Vaccine Company LLC (DVC) has completed Phase I testing of the safety and immunogenicity of an improved cell-cultured smallpox vaccine (CCSV).

For more DVC news, go to news articles.

DVC LLC

DVC Press Releases

About DVC

Services

Partners

Newsroom

DVC Careers

Events

Knowledge Library

Bugs and Drugs Blog